Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
HT-001 is a topical formulation under development for the treatment of patients mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are used for treatment of cancers with EGFR up-regulation (such as non-small cell lung cancer, pancreatic cancer, breast cancer, and colon cancer). However, EGFR inhibitors are often associated with dose-limiting skin toxicities that can result in interruption of treatment. HT-001 is targeted to treat these EGFR-induced skin disorders to allow patients to achieve the best potential outcomes of EGFR therapy.
In July 2019 Hoth entered into a Sponsored Research Agreement with the George Washington University (GW) to explore preclinical pharmacology studies with topically administered HT-001.
HT-001 is currently in the preclinical stage of development.
Upcoming Milestones: Hoth Therapeutics submitted a request for a Pre-IND Meeting with FDA on December 22, 2020 and expects to hear back from the FDA in Q1 2021
January 15, 2020 Hoth Therapeutics Exercises Patent Licensing Option with the George Washington University to Further Develop a Therapeutic for Cancer Patients Suffering Cutaneous Changes Like Rash and Hair Loss, as Well as Other Neurogenic Inflammation Side Effects